Table 2.
Pharmacological mediators with their target molecule, concentration, pretreatment as well as commercial origin.
| Inhibitor | Target | Concentration (μM) | Pre-treatment (h) | Origin |
|---|---|---|---|---|
| U0126 | MEK 1/2 | 5 | 1 | New England Biolabs, Ipswich, USA |
| PP2 | Src-family kinases | 10 | 1 | Merck Millipore, Billerica, USA |
| BAPTA-AM | Intracellular Ca2+ chelation | 200 | 4 | Merck Millipore, Billerica, USA |
| Erlotinib | EGFR | 2.5 | 1 | Santa Cruz Biotechnology,Santa Cruz, USA |